Natera Exceeds 2025 Revenue Guidance with Strong Q4 and Full Year Preliminary Results, Driven by Record Signatera Growth

summarizeSummary

Natera announced preliminary financial results for Q4 and full year 2025, significantly surpassing its previous revenue outlook. The company reported approximately $2.3 billion in full-year revenue, which is about $40 million above the top end of its prior guidance, representing a 35% increase over 2024. Fourth-quarter revenue also saw robust growth of 39% year-over-year, reaching approximately $660 million. This strong performance was fueled by substantial growth in test volumes, particularly in oncology tests, including a record sequential increase in clinical molecular residual disease (MRD) tests. The company also achieved positive cash inflows for both the fourth quarter and the full year, indicating improved operational cash generation. Investors will be looking for additional business updates at the upcoming J.P. Morgan Healthcare Conference.

check_boxKey Events

• Exceeds 2025 Revenue Guidance

  Natera announced preliminary full year 2025 revenues of approximately $2.3 billion, exceeding the top end of its financial outlook by about $40 million, representing a 35% increase over 2024.

• Strong Q4 Revenue Growth

  Preliminary fourth quarter 2025 revenues reached approximately $660 million, marking a significant 39% increase compared to the fourth quarter of 2024.

• Record Oncology Test Volume

  The company processed approximately 233,300 oncology tests in Q4 2025, including 225,300 clinical molecular residual disease (MRD) tests, a 55% increase year-over-year and a record sequential growth quarter for clinical MRD tests.

• Positive Cash Inflows

  Natera achieved estimated cash inflows of approximately $30 million in Q4 2025 and greater than $100 million for the full year 2025.

auto_awesomeAnalysis

Natera announced preliminary financial results for Q4 and full year 2025, significantly surpassing its previous revenue outlook. The company reported approximately $2.3 billion in full-year revenue, which is about $40 million above the top end of its prior guidance, representing a 35% increase over 2024. Fourth-quarter revenue also saw robust growth of 39% year-over-year, reaching approximately $660 million. This strong performance was fueled by substantial growth in test volumes, particularly in oncology tests, including a record sequential increase in clinical molecular residual disease (MRD) tests. The company also achieved positive cash inflows for both the fourth quarter and the full year, indicating improved operational cash generation. Investors will be looking for additional business updates at the upcoming J.P. Morgan Healthcare Conference.